AWARD NUMBER:  W81XWH-07-1-0160

TITLE:  ATF4, A Novel Mediator of the Anabolic Actions of PTH on Bone

PRINCIPAL INVESTIGATOR:  Guozhi Xiao, M.D., Ph.D.

CONTRACTING ORGANIZATION:  University of Pittsburgh
                           Pittsburgh, PA  15260

REPORT DATE:  July 2009

TYPE OF REPORT:  Annual

PREPARED FOR:  U.S. Army Medical Research and Materiel Command
                   Fort Detrick, Maryland  21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
                           Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and
should not be construed as an official Department of the Army position, policy or decision
unless so designated by other documentation.
1. REPORT DATE
1 July 2009

2. REPORT TYPE
Annual

3. DATES COVERED
1 July 2008 – 30 June 2009

4. TITLE AND SUBTITLE
ATF4, A Novel Mediator of the Anabolic Actions of PTH on Bone

5. CONTRACT NUMBER

5a. CONTRACT NUMBER

5b. GRANT NUMBER
W81XWH-07-1-0160

5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S)
Guozhi Xiao, M.D., Ph.D.

E-Mail: xiaog@upmc.edu

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
University of Pittsburgh
Pittsburgh, PA 15260

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT
During the last year of support (from July 1, 2008 to June 30, 2009), our studies have made significant progresses in all aspects of the study: i) we demonstrate that ATF4 increases the expression of cyclin D1, a key factor for cell cycle progression, and osteoblast proliferation; ii) we show that ATF4 prevents osteoblasts from apoptosis in cultured osteoblasts and bone; iii) we also show that PTH stimulation of osteoblast proliferation and survival is dependent upon the presence of ATF4 in vivo; and iv) we demonstrate that intermittent PTH stimulates the expression of Osx and osteoblast-specific gene expression. PTH fails to stimulate Osx expression in Atf4-/- animals. One peer-reviewed research paper and two national meeting abstracts are generated directly from this study during this period of support. In the next year of support, we will: i) determine the molecular mechanism whereby ATF4 mediates PTH stimulation of Osx; ii) determine the molecular mechanism whereby ATF4 promotes osteoblast proliferation and survival; and iii) determine the role of ATF4-Runx2 interactions in PTH-induced osteoblast function.

15. SUBJECT TERMS
ATF4, Runx2, PTH, anabolism, proliferation, apoptosis

16. SECURITY CLASSIFICATION OF:

a. REPORT U
b. ABSTRACT U
c. THIS PAGE U

17. LIMITATION OF ABSTRACT UU

18. NUMBER OF PAGES UU

19. NAME OF RESPONSIBLE PERSON

19a. NAME OF RESPONSIBLE PERSON USAMRMC

19b. TELEPHONE NUMBER (include area code)
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4-7</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>7</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>8</td>
</tr>
<tr>
<td>Conclusion</td>
<td>8</td>
</tr>
<tr>
<td>References</td>
<td>None</td>
</tr>
<tr>
<td>Appendices</td>
<td>8</td>
</tr>
</tbody>
</table>
Introduction

Osteoporosis is a bone disease that affects a large numbers of both men and women including many of our service women and men now in the Armed Forces and VA patients in the United States. It causes a significant amount of morbidity and mortality in patients and is often diagnosed after a fracture occurs. Reducing the risk of osteoporotic and associated fractures of these patients will greatly improve their life quality and survival. Parathyroid hormone (PTH) is the most potent anabolic treatment of osteoporosis currently available. It not only dramatically improves bone mass, but also restores bone microarchitecture and increases bone diameter. All of these mechanisms contribute to increasing bone strength and reducing the risk for fractures. However, the molecular mechanism whereby PTH increases bone formation remains largely unknown. Our central hypotheses in this study are: 1) PTH activates ATF4 by promoting its phosphorylation and protein-protein interactions with Runx2; and 2) ATF4 mediates the anabolic actions of PTH on bone. The long-term goal of this study has been to elucidate the molecular mechanisms underlying the anabolic actions of PTH on bone. Two Specific Aims have been proposed to determine the functional relationships between ATF4 and PTH actions on bone: 1) determine the mechanism whereby PTH regulates ATF4 transcriptional activity; 2) establish whether the anabolic actions of PTH require ATF4 in vivo. Studies determine if ATF4 is required for the anabolic actions of PTH in vivo using ATF4-deficient mice. PTH anabolic activity is evaluated in wild type and Atf4-/- mice. PTH effects are measured using standard biochemical and histomorphometric criteria.

Task 1: To determine the mechanism by which PTH regulates ATF4 and Runx2 transcriptional activity (1-36 months). As described in the last Annual Progress Report, we have established that PTH increases ATF4 expression and activity and that ATF4 is required for PTH induction of Ocn expression in osteoblasts. Thus, ATF4 is a novel downstream target of PTH actions in osteoblasts. We have further defined a novel molecular mechanism mediating ATF4-Runx2 interactions, in which TFIIAγ functions as a bridging protein linking ATF4 and Runx2 and mediates osteoblast-specific osteocalcin gene expression. In order to determine the mechanism where ATF4 regulates osteoblast activity, we examined the effects of ATF4 on osteoblast proliferation and survival (see P1). As shown in P1-Fig. 1B, the number of BMSC colonies was significantly decreased in Atf4-/- mice compared to wt mice. This decrease could be explained by a cell-autonomous defect in proliferation and/or survival or could be secondary to an impaired bone microenvironment due to ATF4 deficiency. To differentiate these possibilities, we conducted MTS assay and [3H] thymidine incorporation assays. Results from MTS assay showed that ATF4-deficient cells grew at significantly reduced rates compared to wt mice (P1-Fig. 1C). This result was further confirmed by the [3H] thymidine incorporation assays showing that [3H] thymidine incorporation into the DNA of Atf4-/- bone marrow stromal cells (BMSCs) was decreased by 4-fold compared to values in wt cells (P1-Fig. 1D). We next determined if ATF4 is required for osteoblast proliferation in vivo using 6-wk-old wt and Atf4-/- mice that were injected with bromodeoxyuridine (BrdU)/fluorodeoxyuridine (FdU) 4 h before sacrifice. 10-µm sections of calvariae were obtained, and proliferating cells from the periosteal surface were counted and normalized to total cells from the same area. In wt calvariae, periosteal osteoblasts proliferated very actively with 60% of the total cells being BrdU-positive (P1-Fig. 2A). In contrast, the percent BrdU-positive osteoblasts were significantly reduced in Atf4-/- calvariae (P1-Fig. 2 B and C). Thus, ATF4 is required for the proliferation of BMSCs or osteoblasts both in vitro and in vivo. As shown in P1-Fig. 3, ATF4-deficient cells showed a significant decrease in the cell distribution into both S and G2/M phases (32% and 45% change, respectively) when compared with values of wt control cells. In contrast, the fraction of the cells in G1 was not reduced by ATF4 deficiency. The protein level of cyclin D1 was markedly decreased in Atf4-/- cells relative to wt control (P1-Fig. 4A). Quantitative real-time RT/PCR analysis shows that the level of cyclin D1 mRNA was reduced by 52% in Atf4-/- cells compared to values in wt controls (P1-Fig. 4B). ATF4 is also required for the proliferation of the pre-osteoblast cell line (MC-4 cells) as demonstrated by siRNA experiments (P1-Fig. 5). Furthermore, overexpression of ATF4 significantly increased the level of cyclin D protein as well as cell
proliferation (P1-Fig. 6 and 7). Taken together, these results clearly establish that ATF4 increases cell proliferation probably via promoting the expression of cyclin D1 and cell cycle progression.

We also found that ATF4 is critical for osteoblast survival. The numbers of apoptotic cells including those with shrinking cytoplasm and chromatin condensation (early apoptosis) and DNA fragmentation (late apoptosis) were increased greater than 5-fold in Atf4−/− BMSCs compared to wt cells (P1-8A-C). To confirm this finding, wt and Atf4−/− BMSCs were stained using the ApopTag Peroxidase In Situ Apoptosis Detection Kit, a modified TUNEL staining that measures DNA fragmentation in situ. As shown in P1-Fig. 8D-F, the percent apoptotic cells in Atf4−/− BMSCs were increased by 1.6-fold when compared to wt cells. To determine if ATF4 deficiency increases osteoblast apoptosis in vivo, 10-µm calvarial sections from wt and Atf4−/− mice were obtained and stained using the same kit. Apoptotic cells that stained brown on the periosteal surface of calvariae were counted and normalized to total cells of the same periosteal surface. As shown in P1-Fig. 8G-I, a significant increase in apoptosis was found in Atf4−/− mice compared to wt controls. Thus, ATF4 protects osteoblasts from apoptosis under physiological condition.

Task 2: To establish whether the anabolic actions of PTH require ATF4 (6-48 months). Studies from the last year’s support clearly establish a critical role of ATF4 in the anabolic effects of PTH on long bones, vertebrae, and calvariae. Furthermore, ATF4 is a positive regulator of osteoblast proliferation and survival as described above. To define the mechanism whereby ATF4 regulates osteoblast function and bone formation in vivo, we next determined whether ATF4 plays a role in PTH regulation of osteoblast proliferation in vivo, sections of tibiae and calvariae from wt and Atf4−/− mice treated with and without intermittent PTH were analyzed for in vivo cell proliferation using a Zymed BrdU immunostaining kit. As shown in Fig 1A, B, and E, in wt mice, PTH increased the percentage of proliferating osteoblasts/preosteoblasts of tibial trabeculae by 2.8-fold relative to vehicle-treated control. Ablation of the Atf4 gene resulted in a 50% decline in basal proliferation. In addition, the PTH-stimulated increase in proliferation was decreased by 40 percent (Fig 1C-E). Similarly, PTH-induced proliferation in calvarial periosteal osteoblasts was also significantly reduced by ATF4 deficiency (Fig 1F-J). Therefore, ATF4 is critical for basal and PTH-stimulated proliferation of osteoblasts/preosteoblasts in vivo.

Mature osteoblasts synthesize and deposit a mineralizing extracellular matrix and become osteocytes. Both osteoblasts and osteocytes can be lost through apoptosis. PTH signaling increases the survival of osteoblasts and osteocytes by reducing apoptosis. ATF4 is anti-apoptotic in osteoblasts as described above. To determine whether ATF4 plays a role in PTH-mediated anti-apoptosis, sections of tibiae were stained with TUNEL and apoptotic cells were assessed. As shown in Fig 1K and L, ATF4 deficiency significantly increased the basal levels of apoptosis. As expected, PTH dramatically reduced apoptotic death of tibial trabecular osteoblasts/osteocytes by 48 percent. Importantly, the PTH-stimulated decrease in apoptotic death was completely abolished in Atf4−/− trabeculae (Fig 1M-O). ATF4 was similarly required for PTH to inhibit apoptosis in cortical osteocytes of tibiae (Fig 1P). Collectively, ATF4 is essential for PTH-mediated inhibition of apoptosis in osteoblasts/osteocytes in vivo.

To begin to address the molecular mechanism underlying the anabolic actions of PTH in bone, we measured the expression of Osterix (Osx) and Runx2 proteins, two critical transcription factors that regulate osteoblast differentiation. We used immunohistochemistry (IHC) to measure Osx in the tibiae and calvariae of wt and Atf4−/− mice with or without 28 d anabolic PTH treatment. As shown in Fig 2, in wt-vehicle-treated tibiae, Osx-positive osteoblasts were only identified in the trabeculae and cortical endosteum close to the growth plate (Fig 2A1, B1, and D1) and were almost undetectable in the same regions close to the marrow (Fig 2C1), indicating that cells in these areas are still in the immature (preosteoblast) state. In contrast, in the wt-PTH group, Osx-positive osteoblasts were identified on all surfaces of trabeculae and endosteum throughout the tibia. PTH increased the total number of Osx-positive cells per tibial section by 3.2-fold in wt mice (Panel 2). ATF4 deficiency reduced the numbers of Osx-positive cells by 50 percent (Panel 3). Strikingly, PTH failed to elevate the numbers of Osx-positive cells in Atf4−/− tibiae. Similar results were obtained in calvariae (Fig 2E). The IHC staining was highly specific since no signal was detected in the IgG control group (Panel 5), in which Osx antibody was omitted.
Fig 1. Effects of PTH on osteoblast proliferation and survival in wt and Atf4−/− bone. A-J. BrdU staining, sections of tibiae (A-D) and calvariae (F-I) were stained using a Zymed BrdU immunostaining kit. Proliferating cells were stained brown (arrows) and non-proliferating cells were stained blue. Proliferating cells on tibial trabecular surface or osteoid (E) or calvarial periosteal surface (J) were counted and normalized to total cells from the same area. K-P, TUNEL staining, sections of tibiae were stained using the ApopTag Peroxidase In Situ Apoptosis Detection Kit. Apoptotic osteoblasts and osteocytes (arrows) were stained brown and non-apoptotic cells were stained blue. Apoptotic cells in the trabecular (O) and cortical bone (P) of tibiae were counted and normalized to the total cells from the same area. *P<0.05 (veh vs. PTH), #P<0.05 (wt-veh vs. Atf4−/−-veh).

Consistent with IHC results, as shown in Fig 2I, Western blot analysis using protein extracts showed that PTH dramatically elevated the level of Osx protein in wt tibiae. In contrast, Osx was not detected by Western blot in extracts from Atf4−/− animals (Fig 2I). The level of Runx2 protein was slightly up-regulated by PTH in the wt group, but not in Atf4−/− group. Unlike Osx, the basal level of Runx2 was not reduced by ATF4 deficiency. PTH1R protein, the major receptor for PTH and PTHrP signaling in osteoblasts, was expressed in endosteal osteoblasts of tibiae (Fig 2F) and periosteal osteoblasts of calvariae and hypertrophic chrodocytes in the growth plate area (unpublished data). PTH1R was only slightly increased by intermittent PTH treatment in vivo as measured by IHC and Western blot analysis. Importantly, ATF4 deficiency did not reduce the level of PTH1R (Fig 6F and I). Therefore, the impaired anabolic response of skeleton to PTH observed in Atf4−/− animals cannot be explained by a reduction in the level of PTH1R. These results clearly demonstrate that: i) intermittent PTH stimulates the expression of Osx and, to a lesser extent, Runx2, ii) PTH fails to stimulate Osx/Runx2 expression in the absence of ATF4, and iii) ATF4 is also required for basal level Osx expression.
Fig 2. PTH fails to promote osteoblast differentiation and maturation in the absence of ATF4.
A-E, IHC analysis of Osx expression, sections of tibiae (A-D) and calvariae (E) were immunohistochemically stained using a specific antibody against Osx protein. The nuclei of Osx-positive cells (i.e., osteoblasts) were stained brown. The nuclei of preosteoblasts and other cells are stained blue. The total numbers of Osx-positive osteoblasts per tibial (G) or calvarial (H) section were counted under microscope. F, sections of tibiae were stained using an antibody against PTH1R protein. I, Western blot analysis, protein extracts were isolated from tibiae and analyzed for Osx, Runx2, and PTH1R proteins. *P<0.05 (veh vs. PTH), #P<0.05 (wt-veh vs. Atf4−/−-veh).

Key Research Accomplishments

- ATF4 increases the expression of cyclin D1, a key factor for cell cycle progression, and osteoblast proliferation in vitro and in vivo.
- ATF4 prevents osteoblasts from apoptosis cultured osteoblasts and in bone.
- PTH stimulation of osteoblast proliferation and survival is dependent upon the presence of ATF4 in vivo.
- Intermittent PTH stimulates the expression of Osx. PTH fails to stimulate Osx expression in Atf4−/− animals. Therefore, ATF4 increases osteoblast differentiation and bone mass probably via up-regulation of Osx, a critical transcription factor for osteoblast differentiation.
Reportable Outcomes

Peer-reviewed paper:


Abstracts:

A2. Xiao, G. Critical role of activating transcription factor 4 in parathyroid hormone-mediated bone formation, MHRF09

Conclusion

During the last year of support, our studies establish that: i) ATF4 regulates the expression of cyclin D1 and osteoblast proliferation; ii) ATF4 prevents osteoblasts from apoptosis in vitro and in vivo; iii) ATF4 mediates PTH stimulation of osteoblast proliferation and survival in vivo; iv) ATF4 mediates PTH stimulation of Osx expression and osteoblast differentiation and maturation.

The knowledge obtained from these studies will significantly enhance our understanding of the molecular mechanism underlying the actions of PTH in osteoblasts and bone and define new potential therapeutic targets for improved treatment of osteoporosis and other metabolic bone diseases.

References

N/A

Appendices

One peer-reviewed research paper: P1
Two national meeting abstracts: A1, A2
Activating Transcription Factor 4 Is Critical for Proliferation and Survival in Primary Bone Marrow Stromal Cells and Calvarial Osteoblasts

Xiaoyan Zhang,1,2 Shibing Yu,1 Deborah L. Galson,1 Min Luo,1 Jie Fan,3 Jian Zhang,1 Youfei Guan,2 and Guozhi Xiao1*

1Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania 15240
2Department of Physiology and Pathophysiology, Peking (Beijing) University Health Science Center, Beijing 100083, China
3Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania 15240

ABSTRACT

Activating transcription factor 4 (ATF4) is essential for bone formation. However, the mechanism of its actions in bone is poorly understood. The present study examined the role for ATF4 in the regulation of proliferation and survival of primary mouse bone marrow stromal cells (BMSCs) and osteoblasts. Results showed that Atf4−/− cells display a severe proliferative defect as measured by multiple cell proliferation assays. Cell cycle progression of Atf4−/− BMSCs was largely delayed with significant G1 arrest. Expression of cyclin D1 was decreased both at the mRNA and protein level. A similar proliferation defect was observed in Atf4−/− calvarial periosteal osteoblasts when compared with wt control. Knocking down Atf4 mRNA by small interfering RNA in MC3T3-E1 subclone 4 preosteoblasts markedly reduced expression of cyclin D1 and cell proliferation. In contrast, overexpression of ATF4 increased cyclin D1 expression as well as cell proliferation in Atf4−/− BMSCs. In addition, apoptosis was significantly increased in Atf4−/− BMSCs and calvarial periosteal osteoblasts relative to wt controls. Taken together, these results for the first time demonstrate that ATF4 is a critical regulator of proliferation and survival in BMSCs and osteoblasts in vitro and in vivo. J. Cell. Biochem. 105: 885–895, 2008. © 2008 Wiley-Liss, Inc.

KEY WORDS: ATF4; OSTEOBLASTS; PROLIFERATION; APOPTOSIS; CELL CYCLE; CYCLIN D1

Activating transcription factor 4 (ATF4), also known as cAMP-response element-binding protein 2 (CREB2) [Karpinski et al., 1992] and Tax-responsive enhancer element B67 (TAXREB67) [Tsujimoto et al., 1991], is a ubiquitous basic leucine-zipper transcription factor that is a member of the ATF/CREB protein family. This family includes cAMP-response element-binding protein (CREB), cAMP-response element modulator (CREM), ATF1, ATF2, ATF3, and ATF4 [Ziff, 1990; Brindle and Montminy, 1992; Meyer and Habener, 1993; Sassone-Corsi, 1994; Hai et al., 1999]. ATF4 functions as both transcriptional repressor and activator by forming homodimers and heterodimers with members of the AP-1 and C/EBP family of protein, or interacting with many other partners, such as human T-cell lymphotropic virus type 1, granulocyte colony-stimulating factor promoter element 1-binding protein, insulin-like growth factor-binding protein-1, NF-E2-related factor 2, c-maf, p300, Zhangfei, factor inhibiting ATF4-mediated transcription, special AT-rich sequence binding protein 2, transcription factor IIAγ, and runt-related transcription factor 2 [Hai and Curran, 1991; Chevray and Nathans, 1992; Nishizawa and Nagata, 1992; Vallejo et al., 1993; Vinson et al., 1993; Motohashi et al., 1997; Reddy et al., 1997; He et al., 2001; Lassot et al., 2005; Xiao et al., 2005; Yu et al., 2005, 2008b; Dobreva et al., 2006; Hogan et al., 2006]. ATF4 expression is up-regulated by several factors/stressors, including oxygen deprivation, endoplasmic reticulum stress, oxidative stress [Ameri et al., 2004; Blais et al., 2004; Roybal et al., 2005].

Abbreviations used: ATF4, activating transcription factor 4; Foxo1, forkhead box D1; BMSCs, bone marrow stromal cells; CDKs, cyclin-dependent kinases; CDKIs, cyclin-dependent kinase inhibitors.

Grant sponsor: NIH; Grant number: DK072230; Grant sponsor: Department of Defense; Grant number: W81XWH-07-1-0160.

*Correspondence to: Dr. Guozhi Xiao, Rm 2E-109, VA Pittsburgh Healthcare System, 151-U, Pittsburgh, PA 15240.
E-mail: xiaog@upmc.edu

Received 27 May 2008; Accepted 17 July 2008  DOI 10.1002/jcb.21888  2008 Wiley-Liss, Inc.
Published online 26 August 2008 in Wiley InterScience (www.interscience.wiley.com).
A role for ATF4 in bone development was established using Atf4-deficient mice [Yang et al., 2004]. Atf4−/− mice have a dramatically reduced bone formation rate and bone mineral density (severe osteoporosis) that persists throughout life. The expression of both osteocalcin (Ocn) and bone sialoprotein (Bsp), both markers for terminally differentiated osteoblasts, was markedly reduced in Atf4-deficient osteoblasts, suggesting a critical role for ATF4 in osteoblast differentiation. The Atf4−/− skeleton is much smaller relative to its wild-type (wt) control littermate, suggesting reduced numbers of bone cells. However, it is not known if ATF4 regulates osteoblast proliferation.

Cell cycle progression is a complex process that regulates cell proliferation. Cell cycle consists of several phases including G1 (from the end of the previous M phase till the beginning of DNA synthesis), S (DNA synthesis), G2 (significant protein synthesis occurs during this phase), and M phase (cell splits itself into two distinct cells) [Sherr and Roberts, 2004]. In addition, quiescent cells are in G0 phase. Cell cycle progression is a highly regulated process in that DNA replication occurs only once in each cycle. Transition from one phase to another is regulated by distinct cyclin-dependent kinases (CDKs) that are regulated by various cyclins, CDK inhibitors, and phosphorylations. Distinct cyclins and appropriate CDKs form complexes that function at different points of the cell cycle [Sherr and Roberts, 2004]. For example, formation of cyclin D1-CDK4/6 complex in early to mid G1 phase activates the kinases that phosphorylate and inactivate the tumor suppressor Rb, a critical step that is necessary for the transition from G1 to S phase [Kato et al., 1994; Sherr, 1994; Zhao et al., 2001]. The activity of cyclin E-CDK2 is periodic and maximal at the G1 to S phase transition [Roberts et al., 1994; Ohmatsu et al., 1995]. Cyclin A1 activates CDK2 and is essential at the G1/S boundary and throughout S phase [Pagano et al., 1992]. In addition, cyclin-CDK complexes also have a noncatalytic role in G1 phase by sequestering proteins of the cip/kip family, including p27kip and p21cip, both CDK2 inhibitors (CDKIs) that negatively regulate cell cycle progression [Hofmann and Livingston, 1996].

Apoptosis is a form of cell death in which a programmed sequence of events leads to the destruction of cells. It occurs in both physiological and pathological conditions when the body needs to eliminate aged cells, unnecessary cells, and unhealthy cells. The caspase family, a set of cysteine proteases that cleave a variety of substrates, plays a crucial role in apoptosis. Caspases are divided into two groups: “initiator” caspases such as caspase-8 and -9 and “executioner” caspases including caspase-3, -6, and -7 [Shi, 2002]. During apoptosis, after being activated by various forms of stress such as inadequate growth factor support and different types of intracellular damage, initiator caspases proteolytically cleave executioner caspases that cause cell death events such as cytoplasm shrinkage, chromatin condensation, and DNA fragmentation. B-cell lymphoma 2 (Bcl-2) is the prototype for a family of mammalian genes encoding the proteins that control mitochondrial outer membrane permeabilization (MOMP) and can be either pro-apoptotic (Bax, BAD, Bak, and Bok) or anti-apoptotic (including Bcl-2, Bcl-XL, and Bcl-w) [Adams, 2003]. Atf4−/− mice are blind due to excessive apoptosis of cells in the lens epithelium [Kato et al., 1994; Sherr and Roberts, 2004], suggesting a critical role for ATF4 in protecting these cells from apoptosis under physiological condition.

The aim of this study was to determine the effects of ATF4 in the regulation of proliferation and apoptosis in primary BMSCs and osteoblasts.

MATERIALS AND METHODS

REAGENTS

Tissue culture media were purchased from Invitrogen (Carlsbad, CA) and fetal bovine serum from HyClone (Logan, UT). Other reagents were obtained from the following sources: Antibodies against cyclins D1, D3, p21, p27, CDK2, and horseradish peroxidase-conjugated mouse or goat IgG from Santa Cruz (Santa Cruz, CA), mouse monoclonal antibody against β-actin from Sigma (St. Louis, MO), BrdU immunostaining kit (Zymed Laboratories Inc., San Francisco, CA) from Invitrogen, ApopTag Peroxidase In Situ Apoptosis Detection Kit from Chemicon (Temecula, CA). Hoechst staining reagent was kindly provided by Dr. Rentian Feng of the University of Pittsburgh. All other chemicals were of analytical grade.

Atf4-DEFICIENT MICE

Breeding pairs of ATF4 heterozygous mice were described previously [Yu et al., 2008a] and used to generate Atf4 wild-type (wt) (Atf4+/+), heterozygous (Atf4+/−) and homozygous mutant (Atf4−/−) mice for this study. All research protocols were approved by the Institutional Animal Care and Use Committee of the VA Pittsburgh Healthcare System, where this study was conducted.

HISTOLOGICAL EVALUATION

Six-week-old wt and Atf4−/− mice were euthanized and calvariae were fixed in 10% formalin at 4 °C for 24 h, decalcified in 10% EDTA (pH 7.4) for 10 days, and embedded in paraffin. Calvariae were then bisected perpendicular to the sagittal suture through the central portion of the parietal bones, parallel to lamboidal and coronal sutures, and embedded in paraffin to obtain sections of a standard area according to the method described by Zhao et al. [2000].

CELL CULTURES AND ISOLATION OF PRIMARY BMSCs

Mouse MC3T3-E1 subclone 4 (MC-4) preosteoblasts were described previously [Xiao et al., 1997; Wang et al., 1999] and maintained in ascorbic acid-free alpha-modified Eagle’s medium (alpha-MEM), 10% fetal bovine serum (FBS), and 1% penicillin/streptomycin (proliferation medium). Isolation of mouse primary BMSCs was described previously [Xiao et al., 2002]. Briefly, 6-week-old male wt and Atf4−/− mice were euthanized. Femurs and tibias were isolated and the epiphyses were cut. Marrow was flushed with alpha-MEM containing 20%FBS and 1% penicillin/streptomycin into a 100-mm dish and the cell suspension was aspirated up and down with a 20-gauge needle in order to break clumps of marrow. The cell suspension was then cultured in a T75 flask in the same medium. After 10 days, cells reached confluency and were ready for experiments.
ELECTROPORATION
Primary BMSCs were transfected using an Amixa Nucleofector device (Cologne, Germany) as described by Nakashima et al. [2005]. Briefly, 2 × 10⁶ BMSCs were suspended in 100 μl solution from Cell Line Nucleofector Kit V (Amixa Biosystems, Cologne, Germany) and mixed with indicated plasmid DNAs. Cells were electroporated using the Program A-23 of the Amixa Nucleofector device. Immediately after electroporation, cells were seeded for experiments.

MTS ASSAY
MTS assay was described previously [Singha et al., 2007]. Briefly, 1 × 10⁴ cells/well were plated in a 96-well plate in 100 μl proliferation medium. Cells were incubated at 37°C for 24 h to allow attachment. The medium was changed every 48 h. At different time points, 20 μl of CellTitre96AQ solution reagent (Promega, Madison, WI) was added into each well and incubated for 2 h. Finally, the absorbance was recorded at 490 nm using a 96-well plate reader.

[³H] THYMIDINE INCORPORATION
Cells were plated in 12-well plates at 5 × 10⁴ cells/well in proliferation medium for 24 h and switched to 0.1% FBS alpha-MEM for another 24 h and [³H] thymidine was then added to a final concentration of 5 μCi/ml and incubated at 37°C for 1 h in proliferation medium. Medium was removed by aspiration, and cells were washed twice with ice-cold serum-free alpha-MEM. Cells were extracted twice with 10% trichloroacetic acid (TCA) on ice for 5 min. TCA precipitates were solubilized by adding 10% SDS for 2 min at room temperature. Cells were harvested, and the amount of radioactivity was measured by liquid scintillation counting (Beckman Instruments, Inc., Fullerton, CA).

BROMODEOXYURIDINE (BrdU) INCORPORATION ASSAY
BrdU labeling reagent was purchased from Invitrogen. BrdU staining was performed using cells cultured in 8-well culture chambers (Nalgene Nunc, NY) or 10-μm sections of calvariae from wt and Atf4⁻/⁻ mice. Cells were cultured in 8-well chamber at a density of 10⁵ cells/well in 400 μl proliferation medium. After 4 days, cells from four identically treated wells per group were labeled with BrdU (1:100 dilution) overnight in the same medium. For calvarial sections, wt and Atf4⁻/⁻ mice were cultured in proliferation medium for 4 days and harvested. 5 × 10⁵ cells were suspended in 1 ml proliferation medium and Vybrant violent dye (Invitrogen) was added to a final concentration of 5 μM and incubated at 37°C for 30 min. The distribution of BMSCs throughout the cell cycle was assessed by flow cytometry using 405 nm excitation and 440 nm emission. The fraction of the population in each phase was determined as a function of DNA content using an FACS with software.

ApopTag PEROXIDASE IN SITU APOPTOSIS DETECTION
This method is based on the classical TUNEL assay to examine apoptosis by detecting DNA fragmentation. Primary BMSCs from wt and Atf4⁻/⁻ mice were cultured in proliferation medium for 4 days and stained using the ApopTag Peroxidase In Situ Apoptosis Detection Kit according to the manufacturer’s instruction. Cells were counterstained with Hematoxlyin. Sections of wt and Atf4⁻/⁻ calvariae (6/group) were prepared and stained using the same kit. Negative controls were made by omitting the terminal deoxynucleotidyl transferase (TdT). All positive (brown) and negative (blue) nuclei were counted. Apoptotic cells on the periosteal surface were counted and normalized to the total cells from the same area.

RNA ISOLATION AND REVERSE TRANSCRIPTION (RT)
Tibias (6/group) were isolated and soft tissues were removed. Tibias were frozen in liquid nitrogen and ground into powder using a mortar and pestle and total RNAs from each group were isolated using the Trizol reagent (Invitrogen) following the manufacturer’s protocol. Reverse transcription (RT) was performed using 1 μg of denatured RNA and 100 pmol of random hexamers (Applied Biosystem, Foster, CA) in a total volume of 25 μl containing 12.5 U MultiScribe reverse transcriptase (Applied Biosystem).

QUANTITATIVE REAL-TIME PCR
Quantitative real-time PCR was performed on an iCycler (BIO-RAD, Minneapolis, MN) using a SYBR® Green PCR Core Kit (Applied Biosystem) and cDNA equivalent to 10 ng RNA in a 50 microliter reaction according to the manufacturer’s instructions. The DNA sequences of mouse primers used for real-time PCR were: cyclin D1 (GenBank Accession number- NM-007631), 5’ GAG GAG GGG GAA GTG GAG GA 3’ (forward, +1,049-bp), 5’ CCT CTG TGC GGC CAC TA 3’ (reverse, +1,170-bp); Fzo1 (GenBank Accession number-NM-019739), 5’ AGA GGC TCA CCC TGT CGC AGA 3’ (forward, +955-bp), 5’ GTG AAG GGA CAG ATT GTG GCC A 3’ (reverse, +1,080-bp); Gapdh (GenBank Accession number-NM-00101303), 5’-CAG TGC CAG CCT GTG CCA GA-3’ (forward, +32-bp), 5’-CTG CAA ATG GCA GCT GTG AC-3’ (reverse, +127-bp). For all primers the amplification was performed as follows: initial denaturation at 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 60 s. Melting curve analysis was used to confirm the specificity of the PCR products. Six samples were run for each primer set. The levels of mRNA were calculated by the ΔCT (the difference between the threshold cycles) method [Wang et al., 2004]. The mRNA level of each gene was normalized to Gapdh mRNA.

WESTERN BLOT ANALYSIS
Cells were washed with cold 1× PBS and lysed in 1× Passive Buffer (Promega) at RT for 20 min. Lysates were clarified by centrifugation (20 min, 13,000g, 4°C). For bone tissues, wt and Atf4⁻/⁻ tibias (6/group) were frozen in liquid nitrogen and ground into powder.
with a mortar and pestle. Samples were solubilized with 1 x Passive Buffer for 20 min on ice and sonicated on ice (3 times, 5 s each) and lysates were then clarified by centrifugation (20 min, 13,000g, 4°C). Protein concentrations were determined by the method developed by Bio-Rad Laboratories, Inc. (Hercules, CA). Twenty-five microgram of total protein were fractionated on a 10% SDS–PAGE gel and transferred onto nitrocellulose membranes (Whatman). The membrane was blocked in 5% nonfat milk in Tris-buffered saline/ Tween-20 (TBST) buffer, probed with antibodies (1:1,000) against cyclins D1, D3, CDK2, p21, and p27 followed by incubation with anti-rabbit or anti-mouse antibodies conjugated with horseradish peroxidase (1:5,000) and visualized using an enhanced chemiluminescence kit (Pierce, Rockford, IL). Finally, blots were stripped 2 times in buffer containing 65 mM Tris–Cl (pH 6.8), 2% SDS, and 0.7% (v/v) β-mercaptoethanol at 65°C for 15 min and re-probed with β-actin antibody (1:2,000) for normalization.

SMALL INTERFERING RNA (siRNA)
MC-4 cells, which contain high levels of Atf4 mRNA, were seeded at a density of 25,000 cells/cm². After 24 h, cells were transfected with mouse Atf4 siRNA (sense: 5'-GAG CAU UCC UUU AGU UUA GUU-3'; antisense: 5'-CUA AAC UAA AGG AAU GCU CUU-3') or negative control siRNA (low GC, Cat #: 12935-200, Invitrogen) [Adams, 2007; Yu et al., 2008a] using LipofectAMINE 2000 (Invitrogen). After 48 h, cells from three identically treated dishes were pooled and harvested for total RNA, followed by quantitative real-time RT-PCR analysis for Atf4, cyclin D1 and Fas01 mRNAs. A second set of mouse Atf4 siRNAs was purchased from Ambion (Cat #: AM16704, ID#: 160775 and 160776) and used to confirm the results using the first set of Atf4 siRNA.

STATISTICAL ANALYSIS
Data was analyzed with GraphPad Prism software. Students’ t-test was used to test for differences between two groups. A one-way ANOVA analysis was used followed by the Dunnett’s test for Figures 1C, 5A–D, 6A–C, and 7A,B. Differences with a P < 0.05 were considered as statistically significant. All experiments were repeated a minimum of 3 times with triplicate samples.

RESULTS
ATF4 DEFICIENCY REDUCES CELL PROLIFERATION IN PRIMARY BMSCs AND CALVARIAL PERIOSTEAL OSTEOBLASTS
To determine if ATF4 plays a role in the regulation of osteoblast proliferation, we performed several experiments. We first determined the effects of ATF4 deficiency on the numbers of total nucleated bone marrow cells, bone marrow from 6-week-old male wt and Atf4−/− mice (6/group) were isolated. After lysing the red blood cells (RBCs) using the RBC lysis buffer (Sigma), the remaining nucleated bone marrow cells were directly counted using a hemacytometer. Bone marrow was flushed out and red blood cells (RBC) were lysed using the RBC lysis buffer. Total nucleated bone marrow cells were counted using a hemacytometer. B: Colony numbers in bone marrow. After lysing the RBCs, the remaining total nucleated bone marrow cells from each mouse (two femurs and two tibias, 6 mice/group) were diluted (1:2,000) and cultured in proliferation medium. 24 h later, the non-adhering cells were removed by washing the cells 2 times with 1/2 PBS. Cells were then cultured in proliferation medium for 10 days. The numbers of colonies were then counted using a microscope. C: MTS assay. Wt and Atf4−/− BMSCs were seeded at a density of 10⁴ cells/well in 96-well plate and cultured in proliferation medium for 0, 2, 4, 6, and 8 days followed by incubation with 20 μl of CellTitre96AQ solution reagent for 2 h. The absorbance was recorded at 490 nm using a 96-well plate reader. D: [3H] thymidine incorporation. wt and Atf4−/− BMSCs were plated in 12-well plates at 5 × 10⁴ cells/well in proliferation medium for 24 h and switched to 0.1% FBS alpha-MEM for 24 h and [3H] thymidine was then added to the culture (proliferation medium) to a final concentration of 5 μCi/ml and incubated at 37°C for 1 h. *P < 0.05 (wt vs. Atf4−/−). Data represent mean ± SD. Experiments were repeated 3 times and qualitatively identical results were obtained.
hemacytometer. As shown in Figure 1A, although the long bones of Atf4−/− mice were significantly shorter and thinner than those of wt mice, surprisingly, we found no significant difference in the numbers of total nucleated bone marrow cells between wt and Atf4−/− mice. This might be accounted for by the relatively larger marrow cavity associated with the reduced cortical and trabecular bone volume observed in the Atf4−/− mice. We next determined whether ATF4 deficiency affects the numbers of total bone marrow stromal cells (BMSCs). After lysing the RBCs as described above, the remaining total nucleated bone marrow cells from each mouse (two femurs and two tibias, 6 mice/group) were diluted (1:2,000) and cultured in proliferation medium. Twenty-four hours later, the non-adhering cells were removed by washing the cells 3 times with 1× PBS. Cells were then cultured in proliferation medium for 10 days. The numbers of colonies from each dish were then counted using a microscope. As shown in Figure 1B, the number of BMSC colonies per mouse (from two femurs and two tibias) was significantly reduced in Atf4−/− group compared to values in the wt group (P < 0.05, wt vs. Atf4−/−). This decrease could be explained by a cell-autonomous defect in proliferation and/or survival or could be secondary to an impaired bone microenvironment due to ATF4 deficiency. To differentiate these possibilities, we conducted MTS and [3H] thymidine incorporation assays. For the MTS assay, 10^4 cells/well of wt and Atf4−/− BMSCs were seeded in 96-well plate and were cultured in proliferation medium for 0, 2, 4, 6, and 8 days. Cell numbers were then measured as described previously [Singha et al., 2007]. As shown in Figure 1C, ATF4-deficient cells grew at significantly reduced rates compared to wt cells. For the [3H] thymidine incorporation assays, wt and Atf4−/− BMSCs were cultured in proliferation medium for 4 days and labeled with [3H] thymidine for 1 h before harvesting. As shown in Figure 1D, [3H] thymidine incorporation into the DNA of Atf4−/− BMSCs was decreased by fourfold compared to values in wt cells (P < 0.05, wt vs. Atf4−/−). It should be noted that the adherent murine BMSC population is contaminated with macrophages, however, macrophages and their precursors would be less proliferative under the culture conditions used, consequently, the proliferation measured is primarily that of BMSCs. To determine if ATF4 is required for osteoblast proliferation in vivo, 6-week-old wt and Atf4−/− mice were injected with bromodeoxyuridine (BrdU)/fluorodeoxyuridine (FdU) 4 h before sacrifice, 10-μm sections of calvariae were obtained, and proliferating cells from the periosteal surface were counted and normalized to total cells from the same area. As shown in Figure 2A, in wt calvariae, periosteal osteoblasts proliferated very actively with 60% of the total cells being BrdU-positive. In contrast, the percent BrdU-positive osteoblasts were significantly reduced in Atf4−/− calvariae (P < 0.05, wt vs. Atf4−/−) (Fig. 2B,C). It should be noted that very few osteocytes (mature osteoblasts) that permeate the bone matrix were stained BrdU-positive in both wt and Atf4−/− calvariae. Thus, ATF4 is required for the proliferation of BMSCs or osteoblasts both in vitro and in vivo.

**ATF4 IS REQUIRED FOR CELL CYCLE PROGRESSION AND CYCLIN D1 EXPRESSION**

To determine whether ATF4 is required for cell cycle progression, we performed flow cytometric analysis to compare the cell distribution across different phases of the cell cycle between wt and Atf4−/− BMSCs. As shown in Figure 3, ATF4-deficient cells showed a significant decrease in the cell distribution into both S and G2/M phases (32% and 45% change, respectively) when compared with values of wt control cells (P < 0.05, wt vs. Atf4−/−). In contrast, the fraction of the cells in G1 was not reduced by ATF4 deficiency (P > 0.05, wt vs. Atf4−/−). Cell-cycle progression from one phase to another is controlled by cyclin-dependent kinases (CDKs) whose activity is mainly regulated by distinct cyclins and cyclin-dependent kinase inhibitors (CDKIs). We examined the effects of ATF4 deficiency on the expression levels of critical cyclin D1, a major regulator of cell cycle progression and cell proliferation, and CDKIs. Wt and Atf4−/− BMSCs were cultured in proliferation medium for
4 days followed by Western blot analysis for cyclin D1, CDK2, p21, and p27. As shown in Figure 4A, the protein level of cyclin D1 was markedly decreased in Atf4−/− cells relative to wt control. In contrast, the level of p21 protein was slightly increased in Atf4−/− cells. Levels of both p27 and CDK2 proteins were low in BMSCs and their relative abundance did not display any significant difference between wt and Atf4−/− cells. Quantitative real-time RT/PCR analysis shows that the level of cyclin D1 mRNA was reduced by 52% in Atf4−/− cells compared to values in wt controls (*P < 0.05, wt vs. Atf4−/−) (Fig. 4B). Note: as expected, minimal Atf4 mRNA was detected by real-time RT/PCR in Atf4−/− cells (Fig. 4B, top).

To determine whether ATF4 is required for proliferation of the pre-osteoblast cell line, MC-4, which expresses high levels of Atf4 mRNA and protein, the cells were transiently transfected with the indicated concentrations of Atf4 siRNA or negative control siRNA (Invitrogen). As shown in Figure 5A, levels of Atf4 mRNA were efficiently reduced by Atf4 siRNA in a dose-dependent manner. In contrast, the negative control (40 nM) did not reduce Atf4 mRNA. Importantly, the level of cyclin D1 mRNA was significantly reduced by Atf4 siRNA in a dose-dependent manner (Fig. 5B). Conversely, the level of Foxo1 mRNA, a factor of the forkhead transcription factor family, was not reduced by Atf4 siRNA (Fig. 5C). Furthermore, knocking-down Atf4 mRNA markedly reduced MC-4 proliferation as measured by both MTS (Fig. 5D) and BrdU incorporation assays (Fig. 5E–G) (*P < 0.05, ctrl siRNA vs. Atf4 siRNA). Similar results were obtained when a different set of Atf4 siRNAs was used in MC-4 cells (data not shown).

**OVEREXPRESSING ATF4 RESCUES THE DEFECT IN CELL PROLIFERATION IN Atf4−/− BMSCs**

We next determined whether overexpression of ATF4 could increase cell proliferation in BMSCs. To this end, we used a Cell Line...
Nucleofector Kit V and a Nucleofector Device from Amaxa Biosystem (Cologne, Germany) because primary mouse BMSCs were transfected with higher than 40% efficiency by using this method (data not shown). To determine the effects of ATF4 overexpression on cyclins expression, Atf4−/− BMSCs were electroporated with increasing amounts of FLAG-ATF4-YFP expression vector (0, 0.5, 1, and 2 μg) [Xiao et al., 2005]. Thirty hours later, cells were harvested for the preparation of total RNA or protein. In addition, as shown in Figure 6A, Atf4 mRNA was efficiently expressed in primary BMSCs in a dose-dependent manner. As shown in Figure 6B,D, ATF4 dose-dependently stimulated cyclin D1 expression both at the mRNA and protein level. In contrast, overexpressing ATF4 failed to elevate the level of cyclin D3 mRNA and protein (Fig. 6C,D). As shown in Figure 7, ATF4 overexpression significantly increased the rate of proliferation in Atf4−/− BMSC as measured by direct cell count, MTS assay, and BrdU staining (P < 0.05, ctrl vs. ATF4). Overexpressing ATF4 similarly increased cyclin D1 expression and cell proliferation in wt BMSCs (data not shown).

Taken together, these results clearly establish that ATF4 increases cell proliferation probably via promoting expression of cyclin D1 and cell cycle progression.

**ATF4 DEFICIENCY INCREASES CELL APOPTOSIS**

ATF4 is known to prevent lens epithelium from apoptosis [Tanaka et al., 1998; Hettmann et al., 2000]. As an initial step to determine if ATF4 regulates apoptosis in BMSCs, wt and Atf4−/− cells were cultured in proliferation media for 4 days and stained by the Hoechst method [Yamanaka et al., 2003]. As shown in Figure 8A–C, the numbers of apoptotic cells including those with shrinking cytoplasm and chromatin condensation (early apoptosis) and DNA fragmentation (late apoptosis) were increased greater than fivefold in Atf4−/− BMSCs compared to wt cells (P < 0.05, wt vs. Atf4−/−). To confirm this finding, wt and Atf4−/− BMSCs were stained using the ApopTag Peroxidase In Situ Apoptosis Detection Kit, a modified TUNEL staining that measures DNA fragmentation in situ. As shown in Figure 8D–F, the percent apoptotic cells in Atf4−/− BMSCs were increased by 1.6-fold when compared to wt cells (P < 0.05, wt vs. Atf4−/−). To determine if ATF4 deficiency increases osteoblast apoptosis in vivo, 10-μm calvarial sections from wt and Atf4−/− mice were obtained and stained using the same kit. Apoptotic cells that stained brown on the periosteal surface of calvariae were counted and normalized to total cells of the same periosteal surface. As shown in Figure 8G–I, a significant increase in apoptosis was found in Atf4−/− mice compared to wt controls (P < 0.05, wt vs.
Atf4<sup>−/−</sup>). Thus, ATF4 protects osteoblasts from apoptosis under physiological condition.

**DISCUSSION**

In this study, we used two complementary approaches to establish the requirement for ATF4 in the regulation of proliferation in primary BMSCs and a preosteoblast cell line (MC-4 cells): (i) loss-of-function studies using Atf4<sup>−/−</sup> or Atf4 siRNA-treated cells demonstrate that cell proliferation is significantly reduced in the absence of ATF4; and (ii) gain-of-function experiments via overexpression of ATF4 show that ATF4 enhances osteoblast proliferation in both wt and Atf4<sup>−/−</sup> BMSCs. In addition, this study reveals that ATF4 protects osteoblasts against apoptosis. Thus, the reduced bone mass
compared to that in Atf4 proliferation by MC-4 cells (Figs. 1C and 5D), the magnitude of inhibition of cell proliferation non-specifically reduces cell proliferation, which could mask the inhibitory effect of the siRNA on cell proliferation. In addition, the Atf4 siRNA may not completely knock down the Atf4 mRNA in MC-4 cells.

Previous studies established that ATF4 is critical for osteoblast differentiation as demonstrated by dramatically reduced expression of osteocalcin and bone sialoprotein mRNA in ATF4-deficient mice [Yang et al., 2004]. The present study demonstrates an essential role for ATF4 in the regulation of BMSC and osteoblast proliferation. ATF4−/− BMSCs and osteoblasts proliferate at a dramatically reduced rate compared to wt cells both in vitro and in vivo. Overexpressing ATF4 in Atf4−/− BMSCs rescues the proliferative defect. Expression of cyclin D1 is highly dependent upon the presence of ATF4 as demonstrated by the dramatic reduction in its mRNA and protein in Atf4−/− BMSCs. Reduced expression of cyclin D1 and possibly other cyclins in Atf4−/− cells leads to a lack of progression from G1 into the S and G2/M phases of the cell cycle. Since the percentage of the population in G1 is not affected by ATF4 deficiency, there must be concomitantly an increase in the percentage of G0 cells (quiescent cells) and/or cells undergoing cell death, thereby reducing overall cell proliferation.

Cyclin D1 is a key sensor and integrator of extracellular signals of cells and plays a critical role in cell cycle progression and proliferation [Stacey, 2003]. The expression level of cyclin D1 has been shown to be rate-limiting in cell proliferation induced by a variety of stimuli [Zhao et al., 2001]. Our results show that ATF4 is a key regulator of cyclin D1 expression in BMSCs or osteoblasts. Levels of cyclin D1 mRNA and protein are significantly reduced in the absence of ATF4. Forced expression of ATF4 efficiently augmented the level of cyclin D1 mRNA as well as cell proliferation in both wt and Atf4−/− cells. Mechanisms whereby ATF4 increases cyclin D1 mRNA remain to be determined. An ATF/CRE site located in the proximal region of cyclin D1 promoter was reported to bind to CREB and AP1 proteins and mediate active transcription of the gene [Sabbah et al., 1999; Nagata et al., 2001; Datta et al., 2007]. It is likely that ATF4 directly binds to this ATF/CRE site and activates transcription. It is also probable that ATF4 activates the cyclin D1 promoter through interactions with CREB and AP1 proteins. Finally, ATF4 can stabilize cyclin D1 mRNA through post-transcriptional mechanisms. Future study will differentiate these possibilities.

The periosteal surface of calvariae is mainly occupied by four cell types: osteoblasts or osteoprogenitors, bone lining cells, and osteoclasts. In rapidly growing animals, osteoblasts or osteoprogenitors are the major cells that cover the surface. In contrast, bone lining cells occupy the majority of the surface in adult or aged bones that have reached peak bone mass. Calvaria, which does not involve endochondral bone formation, has a relatively simple structure relative to other bones such as long bones and vertebrae. In addition, it is easy to histologically localize the osteoprogenitors/osteoblasts on the periosteal surface of calvaria. Therefore, it provides a unique model system for studying the functions of osteoblasts in vivo.
Using this model system, we found that osteoblasts from wt 6-week-old mice proliferate very actively on the periosteal surface (Fig. 2A). Conversely, proliferation of Atf4Cre−/− osteoblasts is significantly reduced (Fig. 2B,C). Thus, an in vivo role for ATF4 in osteoblast proliferation is established. In support of our findings, Masuoka and Townes [2002] showed that Atf4Cre−/− mice have severe fetal anemia due to impaired fetal-liver definitive hematopoiesis associated with a proliferative defect in fetal-liver cells. Furthermore, primary murine embryonic fibroblasts (MEFs) from Atf4Cre−/− mice also display a defect in proliferation [Masuoka and Townes, 2002]. Lastly, transgenic overexpression of ATF4 in the developing lens results in hyperproliferation of lens fiber cells [Hettmann et al., 2000]. These results suggest that ATF4 is critical for proliferation of rapidly growing cells (i.e., BMSCs, osteoblasts, fetal-liver cells, MEFs, and lens fiber cells). Consistent with this notion, ATF4 is usually expressed at high level in rapidly growing tissues or cells [Tanaka et al., 1998; Hettmann et al., 2000; Masuoka and Townes, 2002; Yang et al., 2004].

The numbers of osteoblasts are eventually determined by the relative rate of cell proliferation and death by apoptosis. Experiments from this study establish that ATF4 is anti-apoptotic in BMSCs and osteoblasts. Nevertheless, ATF4 is not a global anti-apoptotic factor since no increase in apoptosis has been observed in BMSCs and osteoblasts. Nevertheless, ATF4 is not a global anti-apoptotic factor since no increase in apoptosis has been observed in BMSCs and osteoblasts. Nevertheless, ATF4 is not a global anti-apoptotic factor since no increase in apoptosis has been observed in BMSCs and osteoblasts. Nevertheless, ATF4 is not a global anti-apoptotic factor since no increase in apoptosis has been observed in BMSCs and osteoblasts. Nevertheless, ATF4 is not a global anti-apoptotic factor since no increase in apoptosis has been observed in BMSCs and osteoblasts. Nevertheless, ATF4 is not a global anti-apoptotic factor since no increase in apoptosis has been observed in BMSCs and osteoblasts. Nevertheless, ATF4 is not a global anti-apoptotic factor since no increase in apoptosis has been observed in BMSCs and osteoblasts. Nevertheless, ATF4 is not a global anti-apoptotic factor since no increase in apoptosis has been observed in BMSCs and osteoblasts.

In summary, this study for the first time establishes that ATF4 is essential for cell proliferation and anti-apoptosis in BMSCs and osteoblasts.

ACKNOWLEDGMENTS

Thanks to Diane George and Dr. Scott Kulich of the VA Pittsburgh Healthcare System for assistance in bone histology and the Nucleofector electroporation transfection, respectively. This work was supported by an NIH Grant DK072230 and a Department of Defense Grant W81XWH-07-1-0160 (to G.X.) and two China National Natural Science Foundation grants NNSF 30530340 and NNSF 30725033 (to Y.G).

REFERENCES


Role of ATF4 in Osteoblast Proliferation and Survival


ATF4 (activating transcription factor 4) is essential for bone formation. However, the mechanism of its actions in bone is poorly understood. The present study examined the role for ATF4 in the regulation of proliferation and survival of primary mouse bone marrow stromal cells (BMSCs) and osteoblasts. Results showed that Atf4-/- cells display a severe proliferative defect as measured by multiple cell proliferation assays. Cell cycle progression of Atf4-/- BMSCs was largely delayed with a significant G1 arrest. Expression of cyclins A1, D1, and D3 was dramatically decreased both at the mRNA and protein level. A similar proliferation defect was observed in Atf4-/- calvarial periosteal osteoblasts in vivo. Knocking down Atf4 mRNA by small interfering RNA in MC3T3-E1 subclone 4 preosteoblasts markedly reduced expression of the cyclins and cell proliferation. In contrast, overexpression of ATF4 increased cyclin D1 expression as well as cell proliferation. In addition, apoptosis was significantly increased in cultured Atf4-/- BMSCs and calvarial periosteal osteoblasts in vivo relative to wt controls. Taken together, this study demonstrates that ATF4 is a critical regulator of proliferation and survival in primary BMSCs and osteoblasts.
CRITICAL ROLE OF ACTIVATING TRANSCRIPTION FACTOR 4 IN PARATHYROID HORMONE-MEDIATED BONE FORMATION

Guozhi Xiao
University of Pittsburgh Medical Center

Background and Objectives: Parathyroid hormone (PTH) is a potent stimulator of bone formation and a proven anabolic agent for the treatment of osteoporosis. However, the mechanism whereby PTH increases bone formation remains poorly understood. The objective of this study was to test our hypothesis that activating transcription factor 4 (ATF4) mediates the anabolic response of skeleton to intermittent PTH.

Materials and Methods: Five-day-old wt and Atf4-/- mice were given daily subcutaneous injections of vehicle (saline) or hPTH(1–34) (60 ng/g body weight) for 28 days. Mice were euthanized 24 hours after the last injection. The effects of this PTH-dosing regimen on long bones (femurs and tibiae), vertebrae, and calvariae were determined by both biochemical and histomorphometric criteria.

Results: Quantitative uCT analysis of femurs showed that Atf4-/- mice had a significant reduction in bone volume/tissue volume (BV/TV), trabecular number (Tb.N), and cortical thickness (Cort.Th) and a marked increase in trabecular space (Tb.Sp) compared with the wt or Atf4+/- littermates. In wt femurs, intermittent PTH increased BV/TV, Tb.N, and trabecular thickness (Tb.Th) by 4.4-fold, 1.7-fold, and 50%, respectively, and decreased Tb.Sp by 1.5-fold. PTH-stimulated bone formation were dramatically reduced (BV/TV, Tb.N, Tb.Sp) or completely abolished (Cort.Th and Tb.Th) in Atf4-/- mice relative to wt mice. Histological analyses show that PTH displayed potent anabolic effects on tibiae, vertebrae, and calvariae, which were markedly reduced in Atf4-/- mice. ATF4 deficiency resulted in a drastic reduction in osteoprogenitors in bone marrow, which impairs the anabolic response of skeleton to PTH. This is probably related to the ability of ATF4 to promote proliferation of osteoblasts/osteoprogenitors as well as survival of osteoblasts and osteocytes, two critical steps for intermittent PTH to increase bone formation. In addition, ATF4 is required for PTH stimulation of osteoblast differentiation.

Conclusion and Impact: This study demonstrates that ATF4 is required for the anabolic actions of PTH in bone and suggests that modulation of the levels and activity of ATF4 may have therapeutic significance for the treatment of metabolic bone diseases such as osteoporosis.

This work was supported by the U.S. Army Medical Research and Materiel Command under W81XWH-07-1-0160 and by a National Institutes of Health grant DK072230.